Combined analysis of SPARC from heterogeneous sources revealed that the Cancer−/GCAF+ group had the best prognosis among the groups; the difference in OS between this group and the Cancer−/GCAFs− group was statistically significant (χ2 = 7.071, P = 0.008). The gene discussed is LYSET; the disease is cancer.